(NewsNation) — DNA testing company 23andMe — and its customers' data — will soon belong to Regeneron Pharmaceuticals.

Regeneron, a biotechnology company, announced Monday that it will "acquire substantially all of the assets" of 23andMe through a $256 million deal.

Will 23andMe sale affect customer data privacy?

Regarding 23andMe's massive DNA database, Regeneron said it plans to process the data "in accordance with the consents, privacy policies and statements, terms of service, and notices currently in effect."

"Through our Regeneron Genetics Center, we have a proven track record of safeguarding personal genetic data, and we assure 23andMe customers that we will apply our high standards for safety and integrity to their data and ongoing consumer genetic services," the company said in

See Full Page